{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:23:46Z","timestamp":1740140626743,"version":"3.37.3"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HHSN268201600018C"],"award-info":[{"award-number":["HHSN268201600018C"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recent clinical trials have evaluated angiotensin-converting enzyme (ACE) inhibitors (ACEis), angiotensin receptor blockers (ARBs), and beta blockers (BBs) in relation to cardiotoxicity in patients with cancer, typically defined by ejection fraction declines. However, these trials have not examined long-term, hard clinical endpoints. Within a prospective study, we examined the risk of heart failure (HF) and coronary heart disease (CHD) events in relation to use of commonly used antihypertensive medications, including ACEis\/ARBs, BBs, calcium channel blockers (CCB), and diuretics, comparing women with and without cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>In a cohort of 56,997 Women's Health Initiative study participants free of cardiovascular disease who received antihypertensive treatment, we used multivariable-adjusted Cox regression models to calculate the hazard ratios (HRs) of developing CHD, HF, and a composite outcome of cardiac events (combining CHD and HF) in relation to use of ACEis\/ARBs, CCBs, or diuretics versus BBs, separately in women with and without cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Whereas there was no difference in risk of cardiac events comparing ACEi\/ARB with BB use among cancer-free women (HR = 0.99 [0.88\u20131.12]), among cancer survivors ACEi\/ARB users were at a 2.24-fold risk of total cardiac events (1.18\u20134.24); p-interaction = .06). When investigated in relation to CHD only, an increased risk was similarly observed in ACEi\/ARB versus BB use for cancer survivors (HR = 1.87 [0.88\u20133.95]) but not in cancer-free women (HR = 0.91 [0.79\u20131.06]; p-interaction = .04). A similar pattern was also seen in relation to HF but did not reach statistical significance (p-interaction = .23).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These results from this observational study suggest differing risks of cardiac events in relation to antihypertensive medications depending on history of cancer. Although these results require replication before becoming actionable in a clinical setting, they suggest the need for more rigorous examination of the effect of antihypertensive choice on long-term cardiac outcomes in cancer survivors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Although additional research is needed to replicate these findings, these data from a large, nationally representative sample of postmenopausal women indicate that beta blockers are favorable to angiotensin-converting enzyme inhibitors in reducing the risk of cardiac events among cancer survivors. This differs from the patterns observed in a noncancer cohort, which largely mirrors what is found in the randomized clinical trials in the general population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0977","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T13:22:29Z","timestamp":1586179349000},"page":"712-721","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative"],"prefix":"10.1093","volume":"25","author":[{"given":"Kerryn W.","family":"Reding","sequence":"first","affiliation":[{"name":"University of Washington School of Nursing, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron K.","family":"Aragaki","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[{"name":"MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Wassertheil-Smoller","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Chubak","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian C.","family":"Limacher","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Gregory","family":"Hundley","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Pauley Heart Center, Richmond, Virginia, USA"},{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ralph","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara Z.","family":"Vitolins","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore M.","family":"Brasky","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel A.","family":"Habel","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California Division of Research, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Chow","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington, USA"},{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca D.","family":"Jackson","sequence":"additional","affiliation":[{"name":"The Ohio State University Department of Medicine, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu","family":"Chen","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Morgenroth","sequence":"additional","affiliation":[{"name":"Seattle Pacific University College of Nursing, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy E.","family":"Barrington","sequence":"additional","affiliation":[{"name":"University of Washington School of Nursing, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Banegas","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Barnhart","sequence":"additional","affiliation":[{"name":"Stony Brook University School of Medicine, Stony Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan T.","family":"Chlebowski","sequence":"additional","affiliation":[{"name":"Harbor-University of California Los Angeles Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"2021122510514733500_onco13295-bib-0001","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1634\/theoncologist.2018-0773","article-title":"Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer","volume":"24","author":"Curigliano","year":"2019","journal-title":"The Oncologist"},{"key":"2021122510514733500_onco13295-bib-0002","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510514733500_onco13295-bib-0003","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J Oncol Pract"},{"key":"2021122510514733500_onco13295-bib-0004","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"suppl 5","key":"2021122510514733500_onco13295-bib-0005","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122510514733500_onco13295-bib-0006","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510514733500_onco13295-bib-0007","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.3747\/co.20.1470","article-title":"Predicting the risk of cardiovascular comorbidities in adult cancer survivors","volume":"20","author":"Tashakkor","year":"2013","journal-title":"Curr Oncol"},{"key":"2021122510514733500_onco13295-bib-0008","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2021122510514733500_onco13295-bib-0009","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cjca.2016.04.014","article-title":"The Cardio-oncology Program: A multidisciplinary approach to the care of cancer patients with cardiovascular disease","volume":"32","author":"Parent","year":"2016","journal-title":"Can J Cardiol"},{"key":"2021122510514733500_onco13295-bib-0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122510514733500_onco13295-bib-0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1532-429X-15-66","article-title":"Understanding cardiovascular injury after treatment for cancer: An overview of current uses and future directions of cardiovascular magnetic resonance","volume":"15","author":"Vasu","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"2021122510514733500_onco13295-bib-0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"key":"2021122510514733500_onco13295-bib-0013","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/138148","article-title":"Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs","volume":"2015","author":"Molinaro","year":"2015","journal-title":"Biomed Res Int"},{"key":"2021122510514733500_onco13295-bib-0014","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2021122510514733500_onco13295-bib-0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-11-318","article-title":"Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101\u2013Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI","volume":"11","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122510514733500_onco13295-bib-0016","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021122510514733500_onco13295-bib-0017","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1634\/theoncologist.2011-0445","article-title":"Administration of angiotensin-converting enzyme inhibitors and beta-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: Marker of risk or cardioprotection in the real world?","volume":"17","author":"Oliva","year":"2012","journal-title":"The Oncologist"},{"key":"2021122510514733500_onco13295-bib-0018","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: Follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2021122510514733500_onco13295-bib-0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy-induced left ventricular dysfunction: Interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"J Card Fail"},{"key":"2021122510514733500_onco13295-bib-0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000343622","article-title":"Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial","volume":"123","author":"Heck","year":"2012","journal-title":"Cardiology"},{"key":"2021122510514733500_onco13295-bib-0021","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510514733500_onco13295-bib-0022","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/1055-9965.EPI-11-0729","article-title":"Cancer survivors: A booming population","volume":"20","author":"Parry","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122510514733500_onco13295-bib-0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","article-title":"Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group","volume":"19","year":"1998","journal-title":"Control Clin Trials"},{"issue":"suppl 9","key":"2021122510514733500_onco13295-bib-0024","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1047-2797(03)00042-5","article-title":"The Women's Health Initiative recruitment methods and results","volume":"13","author":"Hays","year":"2003","journal-title":"Ann Epidemiol"},{"issue":"suppl 9","key":"2021122510514733500_onco13295-bib-0025","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1047-2797(03)00043-7","article-title":"Implementation of the Women's Health Initiative study design","volume":"13","author":"Anderson","year":"2003","journal-title":"Ann Epidemiol"},{"issue":"suppl 9","key":"2021122510514733500_onco13295-bib-0026","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S1047-2797(03)00047-4","article-title":"The Women's Health Initiative Observational Study: Baseline characteristics of participants and reliability of baseline measures","volume":"13","author":"Langer","year":"2003","journal-title":"Ann Epidemiol"},{"key":"2021122510514733500_onco13295-bib-0027","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/aje\/kwr274","article-title":"A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women","volume":"175","author":"Margolis","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2021122510514733500_onco13295-bib-0028","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.111.075929","article-title":"Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative","volume":"125","author":"Cook","year":"2012","journal-title":"Circulation"},{"key":"2021122510514733500_onco13295-bib-0029","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/aje\/kwh314","article-title":"Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative","volume":"160","author":"Heckbert","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2021122510514733500_onco13295-bib-0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/CIRCULATIONAHA.111.066688","article-title":"Racial and ethnic differences in incident hospitalized heart failure in postmenopausal women: The Women's Health Initiative","volume":"126","author":"Eaton","year":"2012","journal-title":"Circulation"},{"key":"2021122510514733500_onco13295-bib-0031","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2012.12.035","article-title":"Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"61","author":"Budoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2021122510514733500_onco13295-bib-0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1009672031531","article-title":"Multi-state models: A review","volume":"5","author":"Hougaard","year":"1999","journal-title":"Lifetime Data Anal"},{"key":"2021122510514733500_onco13295-bib-0033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0962280208092301","article-title":"Multi-state models for the analysis of time-to-event data","volume":"18","author":"Meira-Machado","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"2021122510514733500_onco13295-bib-0034","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<587::AID-SIM358>3.0.CO;2-0","article-title":"Multi-state models for bleeding episodes and mortality in liver cirrhosis","volume":"19","author":"Andersen","year":"2000","journal-title":"Stat Med"},{"key":"2021122510514733500_onco13295-bib-0035","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2011","edition":"2nd ed."},{"key":"2021122510514733500_onco13295-bib-0036","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: Competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"2021122510514733500_onco13295-bib-0037","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ijc.29944","article-title":"Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative","volume":"138","author":"Gong","year":"2016","journal-title":"Int J Cancer"},{"issue":"suppl 15","key":"2021122510514733500_onco13295-bib-0038","article-title":"The CAROLE (CArdiac Related Oncologic Late Effects) Study: A phase II, single-arm feasibility trial","volume":"37","author":"Puckett","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510514733500_onco13295-bib-0039","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/hrt.2003.015552","article-title":"Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: A cardiovascular magnetic resonance study","volume":"90","author":"Bellenger","year":"2004","journal-title":"Heart"},{"key":"2021122510514733500_onco13295-bib-0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia\/New Zealand Heart Failure Research Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2021122510514733500_onco13295-bib-0041","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1001\/jama.292.23.2849","article-title":"Association between cardiovascular outcomes and antihypertensive drug treatment in older women","volume":"292","author":"Wassertheil-Smoller","year":"2004","journal-title":"JAMA"},{"key":"2021122510514733500_onco13295-bib-0042","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2021122510514733500_onco13295-bib-0043","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"2021122510514733500_onco13295-bib-0044","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"2021122510514733500_onco13295-bib-0045","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","article-title":"Cardiovascular protection and blood pressure reduction: A meta-analysis","volume":"358","author":"Staessen","year":"2001","journal-title":"Lancet"},{"key":"2021122510514733500_onco13295-bib-0046","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archinte.1993.00410020010002","article-title":"The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)","volume":"153","year":"1993","journal-title":"Arch Intern Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0977","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0977","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0977","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/8\/712\/41919315\/oncolo_25_8_712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/8\/712\/41919315\/oncolo_25_8_712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:52:26Z","timestamp":1640429546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/8\/712\/6443692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,6]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0977","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2020,4,6]]}}}